Related Experiment Video

Updated: Oct 11, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.2K

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

Georgia Zoumpoulidou1, Carlos Alvarez-Mendoza1, Caterina Mancusi1

  • 1UCL Cancer Institute, University College London, London, UK.

Nature Communications
|December 4, 2021
PubMed

Insights

RB1 tumor suppressor loss in osteosarcoma makes cancer cells sensitive to Poly-ADP-Polymerase inhibitors (PARPi). This PARPi sensitivity, independent of homologous recombination defect, offers a new therapeutic strategy for RB1-mutated cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Loss-of-function mutations in the RB1 tumor suppressor gene are critical in cancer development, particularly osteosarcoma.
  • RB1 deficiency impairs genome maintenance, potentially creating vulnerabilities exploitable by targeted therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of Poly-ADP-Polymerase inhibitors (PARPi) in RB1-defective cancers.
  • To determine the mechanisms underlying PARPi sensitivity in the absence of RB1 function.

Main Methods:

  • Testing the sensitivity of RB1-defective osteosarcoma cell lines and patient-derived xenografts to clinically approved PARPi.
  • Assessing DNA replication checkpoint signaling and homologous recombination defect (HRd) status in response to PARPi treatment.

Main Results:

  • RB1-defective cancer cells, including osteosarcoma, exhibit selective hypersensitivity to PARPi, leading to significant cell death.
  • PARPi treatment prolongs survival in mouse models of RB1-defective osteosarcoma.
  • Sensitivity to PARPi in RB1-deficient contexts is not linked to canonical HRd signatures but requires active DNA replication and involves rapid DNA replication checkpoint activation.

Conclusions:

  • PARPi demonstrate significant efficacy in RB1-defective osteosarcoma, exceeding that observed in BRCA-mutated cancers.
  • PARP1,2 inhibition represents a promising personalized therapeutic strategy for RB1-mutated osteosarcoma and potentially other cancers, extending beyond current HRd-based patient selection criteria.

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.2K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.5K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.5K